BIOLARGO, INC.

Steve: Yeah.

Matt: In abundance. So maybe let's wrap this up. We've got great technology, we've got incredible clinical data, we've got excitement and enthusiasm from the clinical marketplace. We've got early distribution already on board so much faster than most companies. We've got a major partner coming on board. Hopefully some more news about that soon to help people understand more about what that opportunity looks like when you can disclose it.

Steve: Yeah.

Matt: What milestones should investors in Clyra, investors in BioLargo be looking for ahead over the next three to six months? What would be things on your list that you want to deliver and give information to these investors?

Steve: Yeah, I think the milestones that we're working on achieving, which is adoption into systems. Hospital systems, clinic systems, wound care clinics, burn clinics. We also have... Again, we have clinical studies planned, and very proud of the institutions that we're going to be working with. We can't announce those yet, but they're institutions that you say, "Wow, this is the top of the top. This is the top." And so that's what we're focused on. We want to go to the finest institutions with the leading world experts in these areas and have them tell us what they think and put that in the form of a randomized clinical trial that is going to be published and peer-reviewed in the academia and medicine so that we have an unimpeachable data set. And then sales, right?

Steve: I think we'll see that adoption, a very strong upswing in that in 2027. First year out for a medical device company introducing a new product. This year's been a tough year for wound care. There've been some changes in reimbursement on the tissue side that have affected the entire industry, but we're getting through that now. We're getting through that cycle. Probably a really tough year to launch, but I think we're gonna end up with a pretty good year this year. Next year's gonna be really good.

Dennis: Yeah, one of the other things that the show was really evident to me is the role of the antimicrobial to help other products be successful is also very apparent. Because there's a broad field, tissue therapy, all sorts of therapies that are part of the wound healing industry, and all of them need our ingredients, all of them. I mean, we help. We're sort of like the glue that holds them together for the bioburden that allows the body to do its work and heal, right? So it's pretty remarkable. And it positions Clyra as a staple across the entire industry. I think as it unfolds, we'll see more and more strategic alliances come together with major players around the world.

Steve: And again, apologize for taking so much time, but you asked me and I love to tell the story, so I get carried away sometimes.

Matt: No, it's fantastic. I think that's what people need to understand. They need to see that excitement, that enthusiasm, and it's all grounded in real fact, it's in real data, it's in real clinical experience that's underpinning that enthusiasm. And like you said, every time you do the test, the results come back favorable, and now you're excited and enthusiastic to run those trials. So this is fantastic. Gentlemen, I appreciate the time with both of you. Dennis, thank you.